Analysts See $-0.04 EPS for Aurora Cannabis Inc. (ACB)

September 16, 2018 - By Margaret Guttierez

Analysts expect Aurora Cannabis Inc. (TSE:ACB) to report $-0.04 EPS on September, 25.They anticipate $0.03 EPS change or 300.00 % from last quarter’s $-0.01 EPS. After having $-0.05 EPS previously, Aurora Cannabis Inc.’s analysts see -20.00 % EPS growth. The stock increased 2.89% or $0.24 during the last trading session, reaching $8.54. About 25.12 million shares traded or 60.85% up from the average. Aurora Cannabis Inc. (TSE:ACB) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Aurora Cannabis Inc., together with its subsidiaries, produces and distributes medical marijuana products in Canada. The company has market cap of $8.13 billion. The company's products consist of dried cannabis and cannabis oil. It currently has negative earnings. It also operates as a pharmaceutical wholesaler and narcotics dealer of medical marijuana in Germany and the European Union; and produces and sells proprietary systems for the indoor cultivation of cannabis, organic microgreens, vegetables, and herbs.

More notable recent Aurora Cannabis Inc. (TSE:ACB) news were published by: which released: “Emerald Health Therapeutics Stock Surging to Higher Levels” on September 14, 2018, also with their article: “Aurora Cannabis Inc (TSE:ACB) CCO Cam Battley on Spin-out and Canopy Growth Corp – Constellation Brands Tie-up” published on August 19, 2018, published: “The Marijuana Market in Canada Continues to Expand Ahead of Legalization” on September 10, 2018. More interesting news about Aurora Cannabis Inc. (TSE:ACB) were released by: and their article: “VIDEO: The Green Organic Dutchman Holdings Ltd (TSE:TGOD) Acquisitions and Partnerships to Enter Canadian …” published on August 24, 2018 as well as‘s news article titled: “Aurora Cannabis Makes Inroads Into South America With Latest Acquisition” with publication date: September 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.